Buparlisib was developed as a pan-PI3K inhibitor and received fast-track designation by the FDA in combination with the tubulin-targeting drug paclitaxel for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) [201,202]. This evidence concerns the gene PIK3CA and head and neck squamous cell carcinoma.